Immunology & Neurology

UCB

UCB is a Belgian biopharmaceutical company with approximately 8,600 employees worldwide, focused on transforming the lives of patients with severe diseases affecting the immune system and the nervous system. Its marketed portfolio includes certolizumab pegol (an anti-TNF antibody), brivaracetam and lacosamide (ion-channel-modulating antiepileptics), and rozanolixizumab (a neonatal Fc receptor antagonist). UCB's research platforms range from antibody engineering to machine-learning-based drug design. The company maintains long-standing collaborative agreements with epilepsy research centres across Europe and North America and funds the UCB Institute of Allergy and Immunology at leading universities. Scientists partnering with UCB gain access to validated CNS animal models, patient-derived iPSC lines, and proprietary target-screening assays.